synthetic lethality

NEW YORK — September 25, 2026 SELLAS Life Sciences Group presented new preclinical data for SLS009 (tambiciclib) in patient-derived...

NANJING, China and BASILDON, UK — September 18, 2026 IMPACT Therapeutics and Pharmanovia announced that the Committee for Medicinal...

South San Francisco, California, August 19, 2026 IDEAYA Biosciences has entered into a clinical collaboration with Genentech, a member...

SHANGHAI, China, July 27, 2026 IMPACT Therapeutics announced the nomination of IMP3201 as a preclinical candidate (PCC), marking the...

SHANGHAI, July 31, 2026 IMPACT Therapeutics announced an exclusive licensing agreement with Pharmanovia, granting the global specialty pharmaceutical company...

SOUTH SAN FRANCISCO, Calif., July 27, 2026 IDEAYA Biosciences announced the initiation of Part 2 monotherapy expansion in its...

Montreal, Canada | January 29, 2026 — Repare Therapeutics Inc., a clinical-stage precision oncology company, has completed its previously...